Drugs / Ebselen
Ebselen
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01452607 | May → Aug 2006 | cancer, hearing loss disorder | Sound Pharmaceuticals, Incorporated | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06340633 | Dec 2026 expected | hearing loss disorder | Sound Pharmaceuticals, Incorporated | Recruiting | No outcome recorded |
| Phase 2 | NCT04484025 | Oct 2021 → Dec 2023 overdue | COVID-19 | Sound Pharmaceuticals, Incorporated | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT03325790 | Sep 2017 → Apr 2019 | Meniere disease | Sound Pharmaceuticals, Incorporated | Completed | No outcome recorded |
| Phase 2 | NCT02819856 | Jul 2017 → Apr 2023 | drug-induced hearing loss | Sound Pharmaceuticals, Incorporated | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06859788 | Oct 2025 → Dec 2026 expected | Meniere disease | Sound Pharmaceuticals, Incorporated | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04677972 | Aug 2022 → Sep 2023 | Meniere disease | Sound Pharmaceuticals, Incorporated | Completed | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 1 | NCT05117710 Comparator | Apr 2021 → May 2024 | major depressive disorder | University of Oxford | Unknown | No outcome recorded |
| Phase 1/2 | NCT02603081 Comparator | Dec 2015 → Aug 2017 | Meniere disease | Sound Pharmaceuticals, Incorporated | Completed | No outcome recorded |
| Phase 2 | NCT02779192 Comparator | Jun 2026 | noise induced hearing loss | Sound Pharmaceuticals, Incorporated | Withdrawn | No outcome recorded |
| Phase 2 | NCT01451853 Comparator | Jun 2026 | chemotherapy-induced toxicity, head and neck cancer, hearing loss disorder, lung cancer +1 | Sound Pharmaceuticals, Incorporated | Withdrawn | No outcome recorded |
| Phase 2 | NCT04483973 Comparator | Aug 2021 → May 2023 | COVID-19 | Sound Pharmaceuticals, Incorporated | Completed | No outcome recorded |
| Phase 2 | NCT03013400 Comparator | Oct 2017 → Jul 2019 | manic bipolar affective disorder | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT01444846 Comparator | Sep 2011 → Dec 2013 | hearing loss disorder | Sound Pharmaceuticals, Incorporated | Completed | No outcome recorded |
| Phase 2/3 | NCT00762671 Comparator | May 1999 → Oct 2007 | type 1 diabetes mellitus, type 2 diabetes mellitus | Brigham and Women's Hospital | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ebselen | “SPI-1005 is a novel oral drug that contains a glutathione peroxidase mimetic (ebselen) that will be tested in subjects with a history of NIHL at risk for additional NIHL.” NCT02779192 ↗11“SPI-1005, a proprietary oral formulation of ebselen is a small molecule mimic and inducer of the enzyme Glutathione Peroxidase.” NCT01451853 ↗ “200 mg Ebselen oral capsules (SPI-1005), single dose” NCT01452607 ↗ “SPI-1005 Ebselen 200mg Capsule x1” NCT02819856 ↗ |
| Known as | DR-3305 | ChEMBL registry synonym — accepted as the source's own label CHEMBL51085 ↗ |
| Known as | Ebselene | ChEMBL registry synonym — accepted as the source's own label CHEMBL51085 ↗ |
| Known as | Ebseleno | ChEMBL registry synonym — accepted as the source's own label CHEMBL51085 ↗ |
| Known as | NSC-639762 | ChEMBL registry synonym — accepted as the source's own label CHEMBL51085 ↗ |
| Known as | NSC-757883 | ChEMBL registry synonym — accepted as the source's own label CHEMBL51085 ↗ |
| Known as | SPI-1005 | “Oral administration of ebselen (SPI-1005) 400 mg BID for 180 days” NCT06340633 ↗ |
| Action | Inhibit | “IMPase inhibitor” NCT03013400 ↗ |
| Modality | Small molecule | “is a small molecule mimic and inducer” NCT01451853 ↗ |
| Route | Oral | “Subjects began taking placebo or SPI-1005 by mouth for four days beginning two days prior to CV2.” NCT01444846 ↗ |